Valneva
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. They focus on vaccines for diseases such as chikungunya, Lyme disease, Shigella, and Zika, and have leveraged their expertise to commercialize three vaccines and advance a broad range of vaccine candidates. The company actively participates in shareholder meetings, provides extensive documentation, and engages in corporate governance and financial reporting.
Industries
Nr. of Employees
large (251-1000)
Patents
Subunit vaccine for treatment or prevention of a respiratory tract infection
US-12162907-B2
View DetailsSubunit vaccine for treatment or prevention of a respiratory tract infection
US-12162909-B2
View DetailsMethod of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
US-12011477-B2
View Details
Subunit vaccine for treatment or prevention of a respiratory tract infection
US-12162907-B2
View DetailsSubunit vaccine for treatment or prevention of a respiratory tract infection
US-12162909-B2
View DetailsMethod of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
US-12011477-B2
View DetailsProducts
IXCHIQ®
Chikungunya vaccine approved in the United States, Canada and Europe.
Chikungunya vaccine
A single-shot prophylactic vaccine developed by Valneva for the prevention of chikungunya.
IXIARO®
Japanese Encephalitis Vaccine.
DUKORAL®
Cholera Vaccine.
VLA1553
A live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus.
VLA1601
A highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine.
IXCHIQ®
Chikungunya vaccine approved in the United States, Canada and Europe.
Chikungunya vaccine
A single-shot prophylactic vaccine developed by Valneva for the prevention of chikungunya.
IXIARO®
Japanese Encephalitis Vaccine.
DUKORAL®
Cholera Vaccine.
VLA1553
A live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus.
VLA1601
A highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine.